Background Real-world data from different regions are needed to support the external
validity of controlled trials and assess the impact of new oral anticoagulants (NOAC) in …

Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …

Objectives To determine the incremental net health benefits of dabigatran etexilate 110 mg
and 150 mg twice daily and warfarin in patients with non-valvular atrial fibrillation and to …

Background: During its commercialization phase, unprecedented effects of new
medicaments can be discovered. Dabigatran is an anticoagulant approved by Brazilian …

Background: atrial fibrillation (AF) is the most common form of alteration in cardiac rhythm
and associated with more severe episodes of stroke. Treatment with oral anticoagulants …

Aims We aim to determine the optimal dose of dabigatran in Korean patients with atrial
fibrillation (AF). Methods and results We analysed 1834 patients with non-valvular AF …

Edoxaban, an oral direct factor Xa inhibitor, has been found non-inferior to warfarin for
preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation …

Background—Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke
prevention in atrial fibrillation. The purpose of this study was to compare their risks of …

In the past decade, antithrombotic therapy research has focused on the development of new
oral anticoagulant drugs to replace vitamin K antagonists for stroke prevention in patients …

Stroke is the leading cause of morbidity and mortality in patients with atrial fibrillation.
Whereas warfarin reduces the risk of stroke, its interactions with other drugs and food …